Interestingly, structural analyses of non-catalytic domains of TKs have revealed unique modes of kinase regulation [37], which resulted in the development of allosteric inhibitors with improved anti-tumor activities, as reported for asciminib in chronic myeloid leukemia [38]. The gene discussed is CDC42; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.